glp 1 drugs in development Timeline of GLP-1 discovery and clinical development. (a) Key events GLP-1 Costs Explained: Managing Coverage
Description
Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in December 2025 decreased, relative to September 2025 (-6.6%)
The next phase is not one drug
Wang, A
Dulaglutide (Trulicity) Strengths: Once-weekly dosing Easy-to-use auto-injector device Proven cardiovascular benefit Good tolerability profile Considerations: Less weight loss than semaglutide Moderate (not maximum) glucose efficacy Best for: Patients prioritizing convenience and tolerability over maximum efficacy
